Original Report
Trends in antidepressant overdoses†
Mary S. McKenzie MA,
Bentson H. McFarland MD, PhD,
Mary S. McKenzie MA
Department of Psychiatry, Oregon Health & Science University, Portland, OR, USA
Search for more papers by this authorCorresponding Author
Bentson H. McFarland MD, PhD
Department of Psychiatry, Oregon Health & Science University, Portland, OR, USA
Department of Psychiatry, CR-139, Oregon Health & Science University, Portland, OR 97239, USA.Search for more papers by this authorMary S. McKenzie MA,
Bentson H. McFarland MD, PhD,
Mary S. McKenzie MA
Department of Psychiatry, Oregon Health & Science University, Portland, OR, USA
Search for more papers by this authorCorresponding Author
Bentson H. McFarland MD, PhD
Department of Psychiatry, Oregon Health & Science University, Portland, OR, USA
Department of Psychiatry, CR-139, Oregon Health & Science University, Portland, OR 97239, USA.Search for more papers by this author†
No conflict of interest was declared.
Abstract
Background
Debate continues about antidepressants and suicide. However, there are few recent nation-wide data about antidepressant overdoses. The purpose of this study was to describe United States trends from 1983 through 2003 in antidepressant overdoses as well as trends in health care utilization and mortality.
Methods
Data were obtained from the American Association of Poison Control Centers' (AAPPC) Toxic Exposure Surveillance System (TESS), the National Hospital Ambulatory Medical Care Survey (NHAMCS) of emergency departments, and the National Hospital Discharge Survey(NHDS).
Results
Antidepressant overdose reports rose dramatically in the United States (from 0.61 per 10 000 population in 1983 to 3.26 per 10 000 population in 2003) chiefly due to the rise in selective serotonin reuptake inhibitor (SSRI) ingestion. However, fatalities per antidepressant overdose report declined from 73 per 10 000 reported ingestions to 32 per 10 000 ingestions. Tricyclic antidepressant (TCA) overdoses had higher rates of hospitalization (78.7 vs. 64.7% hospitalized) and much higher fatality rates than did SSRI overdose reports (0.73 vs. 0.14% mortality). If the 55 977 SSRI overdoses in 2003 had represented TCA overdoses, then (other things being equal) approximately 410 fatalities would have been expected but only 106 people died. Emergency department visits associated with antidepressant overdose increased along with all emergency department visits. Hospitalization associated with antidepressant overdose increased in the early 1980s but then reached a plateau while overall hospitalizations declined.
Conclusions
The dramatic rise in United States antidepressant overdoses has not been reflected in antidepressant overdose fatalities nor in hospitalizations. If the marked increase in antidepressant overdoses in the United States had involved TCAs rather than SSRIs, then there would have been roughly 300 excess deaths annually. Copyright © 2007 John Wiley & Sons, Ltd.
REFERENCES
- 1 Klein DF. The flawed basis for FDA post-marketing safety decisions: the example of anti-depressants and children. Neuropsychopharmacology 2006; 31: 689–699.
- 2 Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiat 2006; 63: 332–339.
- 3 Hammad TA, Laughren TP, Racoosin JA. Suicide rates in short-term randomized controlled trials of new antidepressants. J Clin Psychopharmacol 2006; 26: 203–207.
- 4 Baldessarini RJ, Pompili M, Tondo L. Suicidal risk in antidepressant drug trials. Arch Gen Psychiat 2006; 63: 246–248.
- 5 Cipriani A, Barbui C, Geddes JR. Editorial: suicide, depression, and antidepressants. Brit Med J 2005; 330: 373–374.
- 6 Juurlink DN, Mamdani MM, Kopp A, Redelmeier DA. The risk of suicide with selective serotonin reuptake inhibitors in the elderly. Amer J Psychiat 2006; 163: 813–821.
- 7 Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. Amer J Psychiat 2006; 163: 41–47.
- 8 Jick S, Dean A, Jick H. Antidepressants and suicide. Brit Med J 1995; 310: 215–218.
- 9 Mann JJ, Kapur S. The emergence of suicidal ideation and behavior during antidepressant pharmacotherapy. Arch Gen Psychiat 1991; 48: 1027–1033.
- 10 Molcho A, Stanley M. Antidepressants and suicide risk: issues of chemical and behavioral toxicity. J Clin Psychopharmacol 1992; 12(Suppl 2): 13S–18S.
- 11 Grunebaum MF, Ellis SP, Li S, Osquendo MA, Mann JJ. Antidepressants and suicide-risk in the United States, 1985–1999. J Clin Psychiat 2004; 65: 1456–1462.
- 12 Farquharson S. Poisoning by tricyclic drugs. Brit Med J 1972; 1(796): 378.
- 13 Simmons AV, Carr D, Ross EJ. Case of self-poisoning with multiple antidepressant drugs. Lancet 1970; 1(7460): 214–215.
- 14 Kapur S, Mieczkowski T, Mann JJ. Antidepressant medications and the relative risk of suicide attempt and suicide. J Amer Med Assoc 1994; 272: 1719–1721.
10.1001/jama.272.22.1719 Google Scholar
- 15 Trindade E, Menon D, Topfer L, Coloma C. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. Can Med Assn 1998; 159: 1245–1252.
- 16 Whyte IM, Dawson AH, Buckley NA. Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. Quart J Med 2003; 96: 369–374.
- 17 Henry JA, Alexander C, Sener E. Relative mortality from overdose of antidepressants. Brit Med J 1995; 310: 221–224.
- 18 Rose JC, Unis AS. A mortality index for postmarketing surveillance of new medications. Amer J Emer Med 2000; 18: 176–179.
- 19 Barbey JT, Roose S. SSRI safety in overdose. J Clin Psychiat 1998; 59(Suppl 15): 42–48.
- 20 D'Mello DA, Finbeiner DS, Kocher KN. The cost of antidepressant overdose. Gen Hosp Psychiat 1995; 17: 454–455.
- 21 Ramchandani P, Murray B, Hawton K, House A. Deliberate self-poisoning with antidepressant drugs: a comparison of the relative hospital costs of cases of overdose of tricylics with those of selective-serotonin re-uptake inhibitors. J Affect Disorders 2000; 60: 97–100.
- 22 Stagnitti MN. Trends in antidepressant use by the U.S. civilian non-institutionalized population, 1997 and 2002. Medical Expenditure Panel Survey Statistical Brief #76. Rockville, Maryland: Agency for Healthcare Research and Quality, May, 2005.
- 23 Whooley MA, Simon GE. Managing depression in medical outpatients. N Eng J Med 2000; 343: 1942–1950.
- 24 Johnson RE, McFarland BH, Nichols G. Changing patterns of antidepressant use in an HMO. Pharmacoeconomics 1997; 11: 274–286.
- 25 Stafford RS, MacDonald EA, Finkelstein SN. National patterns for medication treatment for depression, 1987–2001, (Primary Care Companion). J Clin Psychiat 2001; 3: 232–235.
- 26 Stafford RS, Ausiello JC, Misra B, Saglam D. National patterns of depression treatment in primary care, (Primary Care Companion). J Clin Psychiat 2000; 2: 211–216.
- 27 Olfson M, Marcus S, Druss B, Elinson L, Tanielian T, Pincus HA. National trends in outpatient treatment of depression. J Amer Med Assoc 2002; 287: 203–209.
- 28 Sclar DA, Robison LM, Skaer TL, Galin RS. Trends in the prescribing of antidepressant pharmacotherapy: office-based visits, 1990–1995. Clin Ther 1998; 20: 871–884.
- 29 Pirraglia PA, Stafford RS, Singer DE. Trends in prescribing of selective serotonin reuptake inhibitors and other newer antidepressant agents in adult primary care, (Primary Care Companion). J Clin Psychiat 2003; 5: 153–157.
- 30 Pincus HA, Tanielian TL, Marcus SC, et al. Prescribing trends in psychotropic medications. J Amer Med Assoc 1998; 279: 526–531.
- 31 Zuvekas SH. Prescription drugs and the changing patterns of treatment for mental disorders, 1996–2001. Health Affair 2005; 24(1): 195–205.
- 32 Gunnel D, Ashby D. Antidepressants and suicide: what is the balance of benefit and harm. Brit Med J 2004; 329: 34–38.
- 33 Kairuz T, Truter I, Hugo J, Foxcroft C. Prescribing patterns of tricyclic and selective serotonin reuptake inhibitor antidepressants among a sample of adolescents and young adults. Pharmacoepidemiol Drug Saf 2003; 12: 379–382.
- 34 Watson WA, Litovitz TL, Klein-Schwartz W, et al. 2003 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Amer J Emerg Med 2004; 22: 335–404.
- 35 Watson WA, Litovitz TL, Rodgers GC, et al. 2002 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Amer J Emerg Med 2003; 21: 353–421.
- 36 Litovitz TL, Klein-Schwartz W, Rodgers GC, et al. 2001 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Amer J Emerg Med 2002; 20: 391–452.
- 37 Litovitz TL, Klein-Schwartz W, White S, et al. 2000 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Amer J Emerg Med 2001; 19: 337–395.
- 38 Litovitz TL, Klein-Schwartz W, White S, et al. 1999 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Amer J Emerg Med 2000; 18: 517–574.
- 39 Litovitz TL, Klein-Schwartz W, Caravati EM, Youniss J, Crouch B, Lee S. 1998 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Amer J Emerg Med 1999; 17: 435–487.
- 40 Litovitz TL, Klein-Schwartz W, Dyer KS, Shannon M, Lee S, Powers M. 1997 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Amer J Emerg Med 1998; 16: 443–497.
- 41 Litovitz TL, Smilkstein M, Felberg L, Klein-Schwartz W, Berlin R, Morgan JL. 1996 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Amer J Emerg Med 1997; 15: 447–500.
- 42 Litovitz TL, Felberg L, White S, Klein-Schwartz W. 1995 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Amer J Emerg Med 1996; 14: 487–537.
- 43 Litovitz TL, Felberg L, Soloway RA, Ford M, Geller R. 1994 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Amer J Emerg Med 1995; 13: 551–597.
- 44 Litovitz TL, Clark LR, Soloway RA. 1993 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Amer J Emerg Med 1994; 12: 546–584.
- 45 Litovitz TL, Holm KC, Clancy C, Schmitz BF, Clark LR, Oderda GM. 1992 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Amer J Emerg Med 1993; 11: 494–555.
- 46 Litovitz TL, Holm KC, Bailey KM, Schmitz BF. 1991 annual report of the American Association of Poison Control Centers National Data Collection System. Amer J Emerg Med 1992; 10: 452–505.
- 47 Litovitz TL, Bailey KM, Schmitz BF, Holm KC, Klein- Schwartz W. 1990 annual report of the American Association of Poison Control Centers National Data Collection System. Amer J Emerg Med 1991; 9: 461–509.
- 48 Litovitz TL, Schmitz BF, Bailey KM. 1989 annual report of the American Association of Poison Control Centers National Data Collection System. Amer J Emerg Med 1990; 8: 394–442.
- 49 Litovitz TL, Schmitz BF, Holm KC. 1988 annual report of the American Association of Poison Control Centers National Data Collection System. Amer J Emerg Med 1989; 7: 495–545.
- 50 Litovitz TL, Schmitz BF, Matyunas N, Martin TG. 1987 annual report of the American Association of Poison Control Centers National Data Collection System. Amer J Emerg Med 1988; 6: 479–515.
- 51 Litovitz TL, Martin TG, Schmitz B. 1986 annual report of the American Association of Poison Control Centers National Data Collection System. Amer J Emerg Med 1987; 5: 405–445.
- 52 Litovitz TL, Normann SA, Veltri JC. 1985 Annual Report of the American Association of Poison Control Centers National Data Collection System. Amer J Emerg Med 1986; 4: 427–458.
- 53 Veltri JC, Litovitz TL. 1983 annual report of the American Association of Poison Control Centers National Data Collection System. Amer J Emerg Med 1984; 2: 420–443.
- 54 Gibbons RD, Har K, Bhaumik DK, Mann JJ. The relationship between antidepressnat medication use and rate of suicide. Arch Gen Psychiat 2005; 62: 165–172.
- 55 Marzuk PM, Leon AC, Tardiff K, Morgan EB, Stajic M, Mann JJ. The effect of access to lethal methods of injury on suicide rates. Arch Gen Psychiat 1992; 49: 451–458.
- 56 Meijer WE, Heerdink ER, van Eijk JT, Leufkens HG. Adverse events in users of sertraline: results from an observational study in psychiatric practice in The Netherlands. Pharmacoepidemiol Drug Saf 2002; 11: 655–662.
- 57 Anderson IM, Tomenson BM. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. Brit Med J 1995; 310: 1433–1438.
- 58 Lenzer J. FDA to review ‘missing’ drug company documents. Brit Med J 2005; 330: 7.
- 59 Jick H, Kaye J, Jick S. Antidepressants and the risk of suicidal behaviors. J Amer Med Assoc 2004; 292: 338–343.
- 60 Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo-controlled, randomised controlled trials submitted to the MHRA's safety review. Brit Med J 2005; 330: 385–389.
- 61 Martinez C, Rietbrock S, Wise L, et al. Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. Brit Med J 2005; 330: 389–395.
- 62 Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004; 363(9418): 1341–1345.
- 63 Fortune SA, Hawton K. Deliberate self-harm in children and adolescents: a research update. Curr Opin Psychiatry 2005; 18: 401–406.
- 64 Committee on the Safety of Medicines. Report of the CSM Expert Working Group on the Safety of Selective Serotonin Reuptake Inhibitor Antidepressants. London: Committee on the Safety of Medicines, 2004.
- 65 Medicines and Healthcare products Regulatory Agency. MHRA Highlights Its Recent Advice on SSRIs. Medicines and Healthcare products Regulatory Agency: London, 2005.
- 66 Medicines and Healthcare products Regulatory Agency. Message from Professor G. Duff, chairman, Commission on Human Medicines. Annex 1. Key findings of CSM's Expert Working Group on the Safety of SSRIs. Use of SSRIS in adults—suicidal behavior. London. Medicines and Healthcare products Regulatory Agency, May, 2006.
- 67 Food and Drug Administration. Antidepressant Use in Children, Adolescents, and Adults. Food and Drug Administration Center for Drug Evaluation and Research: Rockville, Maryland, July 12, 2005.
- 68 Food and Drug Administration. FDA Reviews Data for Antidepressant Use in Adults FDA Talk Paper T05–T25. Food and Drug Administration: Rockville, Maryland, July 1, 2005.
- 69 Barbui C, Percudani M, Hotopf M. Economic evaluation of antidepressive agents: a systematic critique of experimental and observational studies. J Clin Psychopharmacol 2003; 23: 145–154.
- 70 Eccles M, Freemantle N, Mason J. North of England evidence- based guideline development project: summary version of guidelines for the choice of antidepressants for depression in primary care. Fam Pract 1999; 16: 103–111.
- 71 National Institute for Clinical Excellence. Clinical Guideline 23: Depression. Management of Depression in Primary and Secondary Care. National Institute for Clinical Excellence: London, 2005.
- 72 Mines D, Hill D, Yu H, Novelli L. Prevalence of risk factors for suicide in patients prescribed venlafaxine, fluoxetine, and citalopram. Pharmacoepidemiol and Drug Saf 2005; 14: 367–372.
- 73 Ables A, Baughman O. Antidepressants: update on new agents and indications. Amer Fam Physician 2003; 67: 547–554.
- 74 Fergusson D, Doucette S, Glass K, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. Brit Med J 2005; 330: 396–402.
- 75 Olfson M, Shaffer D, Marcus S, Greenberg T. Relationship between antidepressant medication treatment and suicide in adolescents. Arch General Psychiat 2003; 60: 978–982.
- 76 Leon AC, Marzuk PM, Tardiff K, Teres JJ. Paroxetine, other antidepressants, and youth suicide in New York City: 1993 through 1998. J Clin Psychiat 2004; 65: 915–918.
Citing Literature
